Innocan Pharma Corp
CNSX:INNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
IL |
|
A
|
Amicus Therapeutics Inc
F:AM6
|
US |
Intrinsic Value
The intrinsic value of Innocan Pharma Corp (INNO) under the Base Case is 5.01 CAD per share. Compared with the current market price of 1.8 CAD, the stock appears Undervalued by 64% .
The intrinsic value is calculated using the DCF method. Net margin recovers from -4.2% last year to 9.5% by 2031. Revenue grows about 16% a year over the next five years, less than a third of its five-year pace of 406%. The forecast years subtract value, so the estimate rests entirely on the years after 2031.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Innocan Pharma Does
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items.
- Headquarters
- Israel IL
- Employees
- 8
- IPO date
- Sep 24, 2019
Earnings Waterfall
Innocan Pharma Corp
The intrinsic value for Innocan Pharma Corp (INNO) under the Base Case is 5.01 CAD.
Compared with the current market price of 1.8 CAD, the stock appears Undervalued by 64% .